Sequencing in EGFR-Mutated NSCLC: Does Order Matter?
|
|
- Aron Townsend
- 5 years ago
- Views:
Transcription
1 Sequencing in EGFR-Mutated NSCLC: Does Order Matter? Maximilian J. Hochmair, MD Otto Wagner Hospital Vienna, Austria
2 Disclosures Honoraria: AstraZeneca, AbbVie, Pfizer, Boehringer Ingelheim, Roche, MSD, BMS, Takeda, Lilly 2
3 In the 1990s, a thoracic oncologist s life was simple Lung cancer Platinum + etoposide Very few treatment options! 3
4 now it s much more complex STAGE IV DIAGNOSIS Nonsquamous cell Molecular tests Squamous cell EGFR positive ALK/ROS1 positive BRAF pos. EGFR negative/alk negative Targeted Therapy (1st/2nd EGFR TKI or 1st ALK) Treat to progression Dabrafenib/ Trametinib Treat to progression Testing IHC PD-L1 Expression Pembrolizumab in PD-L1 50% Chemotherapy in PD-L1 <50% Targeted Therapy (2nd/3rd-Gen EGFR or ALK) Poor PS (2) Treat to progression Good response Platinum Doublet (+/- bevacizumab) 4-6 cycles Maintenance: Pem or Bev (or erlotinib) Single-Agent Chemo Treat to progression Platinum Doublet +/-Necitumumab 4-6 cycles Maintenance: erlotinib Stable Disease Progression Chemotherapy Testing for MET?/PD-L1 Expression? EGFR = epidermal growth factor receptor; ALK = anaplastic lymphoma kinase; ROS1 = c-ros oncogene 1; TKI = tyrosine kinase inhibitor; IHC = immunohistochemistry; PD-L1 = programmed death ligand 1; PS = performance status; Pem = pembrolizumab; Bev = bevacizumab. Chemotherapy Taxol +/- nintedanib Taxol +/- ramucirumab Platinum doublet (reind.) Gemcitabine/navelbine Pemetrexed Erlotinib/Afatinib More likely if PS bad/ patient s wish Immunotherapy Experimental drug SOP OWS 2018 according to Hochmair. 4
5 Case Woman, aged 45 years Healthy 10 pack years Coughing + headache 5
6 X-ray: June
7 CT Scan 7
8 MRI of the Brain MRI = magnetic resonance imaging. 8
9 Case (cont d) Woman, aged 45 years Healthy 10 pack years Coughing + headache NSCLC (adenocarcinoma) right lower lobe T4 N2 M1b EGFR status: exon Del19 (pleural effusion) 9
10 6 Weeks With Afatinib 10
11 6 Weeks With Afatinib 11
12 6 Weeks With Afatinib 12
13 Conclusions Treatment decision was afatinib based on its efficacy data, brain-penetrating ability, and personal experience With the introduction of osimertinib, the decision would remain unchanged because of a lack of treatment options after osimertinib failure 13
14 First-, Second-, and Third-Generation EGFR TKIs Are Not Equal: Activity Against EGFR Mutations Wild-type EGFR Intrinsic mutant EGFR ErbB heterodimers eg, Her2: ErbB3 Acquired T790M EGFR K Kinase domain K K K K K K K Drug Metabolised by CYP Enzymes Possible Drug-Drug Interactions Erlotinib Gefitinib 1st-generation TKI EGFR inhibition Activity range Reversible binding to wild-type and mutant EGFR Inactive on T790M mutant Erlotinib yes yes Gefitinib yes yes Afatinib Dacomitinib 2nd-generation TKI ErbB family blockade Activity range Irreversible covalent binding to EGFR, ErbB2, and ErbB4 to inhibit all ErbB family signalling Broader activity to overcome EGFR TKI resistant mutations Afatinib no limited Dacomitinib yes yes Osimertinib 3rd-generation TKI EGFR mutant specific inhibitor Activity Irreversible covalent binding to mutant EGFR Specificity for EGFR T790M mutant; EGFR wild-type sparing Range Osimertinib yes yes CYP = cytochrome. Girard. Future Oncol. 2018;14:1117; Cross et al. Cancer Discov. 2014;4:1046; Li et al. Oncogene. 2008;27:4702; Peters et al. Cancer Treat Rev. 2014;40:917; TAGRISSO Prescribing Information. March
15 First- and Second-Generation TKIs Improve PFS Compared With Chemotherapy RR (%) PFS (mo) OS (mo) TKI Study TKI Chemo TKI Chemo TKI Chemo Gefitinib IPASS 1, Gefitinib F-Signal Gefitinib WJTOG NR Gefitinib NEJ002 5, Erlotinib EURTAC Erlotinib ENSURE Erlotinib OPTIMAL 9, Afatinib a LL3 11, Afatinib a LL6 12, a Data for patients with common mutations only. PFS = progression-free survival; RR = response rate; OS = overall survival. 1. Fukuoka et al. J Clin Oncol. 2011;29:2866; 2. Mok et al. N Engl J Med. 2009;361:947; 3. Han et al. J Clin Oncol. 2012; 30:1122; 4. Mitsudomi et al. Lancet Oncol. 2010;11:121; 5. Maemondo et al. N Engl J Med. 2010;362:2380; 6. Inoue et al. Ann Oncol. 2013;24:54-59; 7. Rosell et al. Lancet Oncol. 2012;13:239; 8. Wu et al. Ann Oncol. 2015;26:1883; 9. Zhou et al. Lancet Oncol. 2011;12:735; 10. Zhou et al. Ann Oncol. 2015;26:1877; 11. Sequist et al. J Clin Oncol. 2013;31:3327; 12. Yang et al.lancet Oncol. 2015;16:141; 13. Wu et al. Lancet Oncol. 2014;15:
16 Estimated OS probability Estimated OS probability Mutational Subgroup Impacts Treatment Choice: OS in Del19 Subgroups in LUX-Lung 3 and 6 LUX-Lung 3 LUX-Lung Afatinib (n=112) Cis/Pem (n=57) Median, mo Afatinib (n=124) Cis/Gem (n=62) Median, mo HR (95% CI) P value 0.54 ( ) P= HR (95% CI) P value 0.64 ( ) P= Afatinib Cis/Pem 0.6 Afatinib Cis/Gem Months No. at risk Afatinib Cis/Pem No. at risk Afatinib Cis/Gem Months Cis = cisplatin; Gem = gemcitabine; HR = hazard ratio; CI = confidence interval. Yang et al. Lancet Oncol. 2015;16:
17 ORR (%) PFS (%) First- and Second-Generation EGFR TKIs Are Not Equal: Antitumour Activity Afatinib vs gefitinib as first-line treatment of patients with EGFR mutation positive NSCLC (LUX-Lung 7): a phase IIB, open-label, randomised, controlled trial 80% 60% 40% P=0.002 P=0.150 P= Afatinib (n=160) 73% 75% 56% 66% 69% 42% % Gefitinib (n=159) Median, mo HR (95% CI) P value 0.74 ( ) Afatinib Gefitinib 20% 0% ITT Del19 L858R Afatinib Gefitinib 16% 20 16% 0 7% Months Afatinib Gefitinib Corral et al. Ann Onc. 2017;28 (suppl 2):ii28. 17
18 Probability of PFS First- and Second-Generation EGFR TKIs Are Not Equal: Antitumour Activity ARCHER 1050: Dacomitinib vs Gefitinib (excluding CNS metastases) ARCHER 1050: Study Design PFS: Blinded Independent Review (ITT population) Phase III, randomised, open-label study to evaluate dacomitinib as an alternative first-line treatment for patients with advanced NSCLC with an EGFR-activating mutation 1.0 Dacomitinib (n=227) Gefitinib (n=225) Advanced NSCLC with EGFR-activating mutation(s) No prior systematic treatment of advanced NSCLC No CNS metastasis No prior EGFR TKI or other TKI ECOG PS 0, 1 R 1:1 (N=452) Dacomitinib 45 mg PO qd (N=227) Gefitinib 250 mg PO qd (N=225) Primary endpoint PFS by blinded independent review 256 PFS events PFS HR (50% ) 90% power 1-sided ɑ=0.025 mpfs: 14.3 vs 9.5 months Number of events, n (%) 136 (59.9%) 179 (79.6%) Median PFS (95% Cl) 14.7 ( ) 9.2 ( ) HR (95% Cl) PFS rate 30.6% vs 9.6% 0.59 ( ) P< Dacomitinib Gefitinib ++ Censored No. at risk Months Dacomitinib Gefitinib CNS = central nervous system; ECOG PS = Eastern Cooperative Oncology Group performance status; PO = orally; QD = once daily; mpfs = median progression-free survival. ClinicalTrials.gov. Accessed October 3, 2018; Mok et al. J Clin Oncol. 2017;35(suppl; abstr LBA9007); Wu et al. Lancet Oncol. 2017;18:
19 Safety Second- or Third-Generation TKIs vs First-Generation TKIs LUX-Lung 7 1,2 ARCHER FLAURA 4 Afatinib (n=160) Gefitinib (n=159) Dacomitinib (n=227) Gefitinib (n=225) Osimertinib (n=279) Gefitinib/ Erlotinib (n=277) Treatment discontinuation rate 6.3% 6.3% 10.0% 7.0% 13.0% 18.0% Most common grade 3 AEs Diarrhoea: 12% Rash/acne: 9% Liver enzyme elevation: 9% Rash/acne: 3% Acne: 14% Diarrhoea: 9% Paronychia: 8% Liver enzyme elevation: 9% Paronychia: 1% Diarrhoea: 2% Pneumonia: 2% Decreased appetite: 3% Diarrhoea: 3% Pneumonia: 2% Decreased appetite: 2% AEs = adverse events. 1. Park et al. Lancet Oncol. 2016;17:577; 2. Paz-Ares et al. Ann Oncol. 2017;28:270; 3. Wu et al. Lancet Oncol. 2017;18:1454; 4. Soria et al. N Engl J Med. 2018;378:
20 Estimated PFS probability Dose Reduction of Afatinib Decreased Drug-Related AEs Without Impacting Efficacy The effects of afatinib dose modification on safety and efficacy were assessed in the LUX-Lung 3 trial <40 mg for First 6 mo (n=105) 40 mg for First 6 mo (n=124) Median PFS, mo HR (95% CI) P value 1.25 ( ) <40 mg for first 6 mo 40 mg for first 6 mo 0.2 No. at risk <40 mg in first 6 mo 40 mg for first 6 mo Months As in the LUX-Lung trials, real-world afatinib dose adjustments reduced the frequency and intensity of ADRs without impacting efficacy (RealGiDo study) Median time on treatment was 18.7 months and was not impacted by reduced starting dose or dose modification (19.4/17.7/19.5 for patients who started on 30 mg/reduced to <40 mg/remained on 40 mg) 1. Halmos et al. WCLC P ; 2. Yang et al. Ann Oncol. 2016;27:
21 TKI Resistance: Tissue + ctdna EGFR T790M Is the Most Common Resistance Mechanism to First- and Second-Generation EGFR TKIs Piotrowska et al. Multidisciplinary Thoracic Cancers Symposium Abstract 1. 21
22 Assessment of T790M Mutation Status in Cell-Free Plasma DNA 25% 71% 4% 76% Buder et al. J Thorac Oncol. 2018;13:
23 Probability of PFS Osimertinib vs Chemotherapy in T790M+ NSCLC AURA3 Female, 64% Asian, 65% Never smoker, 68% CNS metastases, 34% Median PFS (mo) (95% Cl) Osimertinib Platinum/pemetrexed 10.1 ( ) 4.4 ( ) No. of patients BICR: PFS 11.0 months HR for disease progression or death, 0.30 (95% CI, ) P< Osimertinib Plat/pem AEs grade 3: 6% 34% No. at risk Osimertinib Months Platinum/pemetrexed BICR = blinded independent central review. Mok et al. N Engl J Med. 2017;376:
24 Estimated Probability Time on Osimertinib: First-line Afatinib Followed by Osimertinib Pooled Analysis LUX-Lung 3, 6, Sequist et al. Ann Oncol. 2017;28(suppl 2):ii28. 0 Median time on treatment: 20.2 mo Osimertinib treatment (mo) 72% were 3rd line No. at risk: Afatinib Post-hoc analysis from LUX-Lung 3/6/7 (n=37), corresponding to 6% of patients treated with afatinib in the trials. Osimertinib was not yet approved at time of recruitment. Based on approval and evidence it could be assumed that all patients were T790M positive. 24
25 FLAURA Study Design Patients with locally advanced or metastatic NSCLC Key inclusion criteria Aged 18 years a WHO performance status 0/1 Exon 19 deletion/l858r (enrollment by local b or cental c EGFR testing) No prior systemic anticancer/ EGFR-TKI therapy Stable CNS metastases allowed Endpoints Stratification by mutation status (Exon 19 deletion/l858r) and race (Asian/non- Asian Osimertinib (80 mg PO qd) (n=279) Randomised 1:1 Gefitinib (250 mg PO qd) or Erlotinib (150 mg PO qd) (n=277) d Primary endpoint: PFS based on investigator assessment (according to RECIST 1:1) The study had 90% power to detect an HR of 0.71 (representing an improvement in median PFS from 10 months to 14.1 months) at a 2-sided alpha level of 5% Secondary endpoints: objective response rate, duration of response, disease control rate, depth of response, OS, patient-reported outcomes, safety RECIST 1:1 assessment every 6 weeks e until objective progressive disease Crossover was allowed for patients in the erlotinib or gefitinib arm who could receive open-label osimertinib upon central confirmation of progression and T790M positivity FLAURA data cut-off: 12 June 2017, NCT a 20 years in Japan, b With central laboratory assessment performed by sensitivity; c Cobas EGFR Mutation Test (Roche Molecular Systems); d Sites to select either gefitinib or erlotinib as the sole comparator prior to site initiation; e Every 12 weeks after 18 months. WHO = World Health Organization; RECIST 1.1: Response Evaluation Criteria In Solid Tumors version 1.1. Soria et al. N Engl J Med. 2018;378:
26 Probability of PFS Probability of OS First- and Third-Generation EGFR TKIs Are Not Equal: Antitumour Activity PFS in FLAURA Median PFS (95% Cl) HR (95% Cl) P value Osimertinib (n=279) Erlotinib or gefitinib (n=277) 17.7 ( ) 9.7 ( ) 0.45 ( ) P< FLAURA OS Data Are Immature (25% Maturity) Osimertinib Erlotinib or gefitinib No. of patients Median OS (95% CI), mo NC (NC-NC) NC (NC-NC) Osimertinib 0.4 Osimertinib Erlotinib or gefitinib No. at risk 0.2 Months Osimertinib Erlotinib or gefitinib NC = not calculated. Data cut-off 12 June Tick marks indicate censored data. Soria et al. N Engl J Med. 2018;378:113. Erlotinib or gefitinib No. at risk Osimertinib Erlotinib or gefitinib HR for death, 0.63 (95% CI, ) P= Months 26
27 Probability of PFS Subsequent Therapies in FLAURA Osimertinib (n=279) 35 Received FST (n=82) 29% received subsequent therapy after osimertinib, mostly chemotherapy st gen EGFR TKI (n=277) Received FST (n=129) Patient Disposition Received first subsequent (second-line) therapy No subsequent therapy (dead) No subsequent therapy (alive) Still on study treatment First Subsequent (Second-Line) Therapies Other targeted therapy Non platinum based chemotherapy Platinum-based chemotherapy Osimertinib EGFR-TKI containing regimen, other than osimertinib FST = First subsequent therapy. Soria et al. N Engl J Med. 2018;378:113 27
28 Acquired Resistance Mechanisms After First-Line Osimertinib (FLAURA) (N=91) EGFR mutations Unknown MET amplifications Other The most frequent resistance mechanisms for osimertinib were MET amplification (15%) and EGFR C797S mutation (7%) Rudin C, discussant of Ramalingam et al. ESMO LBA50. 28
29 Treatment Sequences in EGFR-Mutant NSCLC After First-Line EGFR TKI Except if molecular target First-/Second-Generation TKI T790M+ Osimertinib Chemotherapy T790M- Other Chemotherapy MET/HER2 inhibitor TKI rechallenge? Chemotherapy? Immunotherapy Osimertinib Chemotherapy Except if molecular target Need Mature OS and Treatment Sequences From FLAURA Girard. Future Oncol. 2018;14:
30 Afatinib Followed by Osimertinib: A Real-World Study (GioTag) REAL-WORLD STUDY ON SEQUENTIAL THERAPY IN PATIENTS WITH EGFR MUTATION POSITIVE ADVANCED NSCLC STUDY OBJECTIVES Primary objective A retrospective review to determine the time on treatment a of afatinib as first-line therapy in EFGR mutation positive (M+) followed by osimertinib for T790M resistance mutation patients in a real-world setting Secondary objective To collect data on the acquired resistance mechanism to osimertinib 204 PRESELECTED PATIENTS EGFR M+ (Del19, L858R) advanced NSCLC Based on existing data from medical records Data collection between Q and Q a Time on treatment defined from the start of first-line treatment until the end of second-line treatment or death date by any cause. b Randomised controlled trials (RCTs) are designed to assess the efficacy and safety of study drugs under well-defined conditions and in selected patient populations. In contrast, real-world studies include everyday patients with characteristics which might preclude their participation in a RCT. Real-world studies are complementary to RCTs, and explore patient outcomes in populations more representative of clinical practice than perspective clinical trials. Real-world studies are essential for capturing clinically relevant data at the point of care, and providing clinically meaningful insights which can be applied to patient care. Accessed October 9, 2018; Hochmair M et al. Future Oncol Oct 19; doi: /fon
31 Baseline Characteristics (N=204) Median (range) Ethnicity ECOG EGFR Start of afatinib n (%) Female 110 (53.9) Age (years) 60.0 (30 86) Weight (kg); BMI (kg/m²) 70.2 (37-116); 25.3 ( ) Caucasian 120 (58.8) African-American 18 (8.8) Asian 50 (24.5) Stage IV 197 (96.6) Brain mets 21 (10.3) 0 43 (21.2) (54.2) 2/3 31 (15.3) T790M 0 (0.0) Del (73.5) L858R 53 (26.0) Del19 + L858R 1 (0.5) Hochmair M et al. Future Oncol Oct 19; doi: /fon
32 Treatment probability Time on Treatment for the Sequence Afatinib-Osimertinib Afatinib followed by osimertinib Median time (mo), 90% CI N=204 Events ( ) % still on treatment Time (months) No. at risk Afa-Osi Hochmair M et al. Future Oncol Oct 19; doi: /fon CI = confidence interval. 32
33 Survival probability Survival Rates (from Start of Afatinib) % Afatinib followed by osimertinib 2-year survival rate (maturity) N=204 Events 63 79% (50%) Time (months) No. at risk Afa-Osi Hochmair M et al. Future Oncol Oct 19; doi: /fon
34 Treatment probability Time on Treatment for the Sequence by EGFR Subgroup Median time (mo), 90% CI Del19 (n=150) L858R (n=53) Events ( ) 19.1 ( ) Del 19 L858R Time (months) No. at risk Del L858R Hochmair M et al. Future Oncol Oct 19; doi: /fon
35 Time on Treatment for the Sequence by Baseline ECOG Hochmair M et al. Future Oncol Oct 19; doi: /fon
36 Conclusion Afatinib and osimertinib are highly effective in EGFR mutation positive patients However, there are limited treatment options after osimertinib failure and no mature OS data so far The sequence of afatinib followed by osimertinib for T790M+ patients is feasible and delivers a combined time on treatment of 28 months as assessed in a real-world setting Sequencing should be considered for all patients 36
Emerging Algorithm for Optimal Sequencing of EGFR TKIs in EGFR Mutation Positive NSCLC
Emerging Algorithm for Optimal Sequencing of EGFR TKIs in EGFR Mutation Positive NSCLC Keunchil Park, MD, PhD Samsung Medical Center, Sungkyunkwan University School of Medicine Faculty Disclosure Consulting
More informationEGFR TKI sequencing: does order matter?
EGFR TKI sequencing: does order matter? Nicolas Girard Thorax Institut Curie-Montsouris, Paris, France In Switzerland, afatinib is approved as monotherapy for patients with non-small cell lung cancer (Stage
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and Manchester University Hospital Manchester, UK Outline Data on first-line Overcoming T790M mutation
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Data on first-line Overcoming T790M
More informationImproving outcomes for NSCLC patients with brain metastases
Improving outcomes for NSCLC patients with brain metastases Martin Schuler West German Cancer Center, Essen, Germany In Switzerland, afatinib is approved as monotherapy for patients with non-small cell
More informationManagement Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors
Management Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors Conor E. Steuer, MD Assistant Professor The Winship Cancer Institute of Emory University July 27, 2017 1 Lung Cancer One
More informationState of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD
State of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD Professor and Chair Arthur & Rosalie Kaplan Chair Medical Oncology and Therapeutics Research Nothing to disclose DISCLOSURE Objectives Lung
More informationMolecular Targets in Lung Cancer
Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck
More informationOptimum Sequencing of EGFR targeted therapy in NSCLC. Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey
Optimum Sequencing of EGFR targeted therapy in NSCLC Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey Lung cancer NSCLC SCLC adeno squamous EGFR ALK ROS1 BRAF HER2 KRAS EGFR Transl Lung Cancer
More informationQuale sequenza terapeutica nella malattia EGFR+
Trattamento della malattia avanzata oncogene-addicted Quale sequenza terapeutica nella malattia EGFR+ Chiara Bennati AUSL della Romagna Ravenna, Italy A matter of fact Outline Can we improve PFS/OS with
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationMaking the first decision: EGFR mutation-positive NSCLC in the advanced setting
ELCC May 217, Switzerland Making the first decision: EGFR mutation-positive NSCLC in the advanced setting Noemí Reguart, MD, PhD Hospital Clínic de Barcelona, Spain Disclosures Consultant or Advisory Role
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationRecent Advances in Lung Cancer: Updates from ASCO 2017
Recent Advances in Lung Cancer: Updates from ASCO 2017 Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University of Pennsylvania 6/15/2017
More informationTargeted Therapy for NSCLC: EGFR and ALK Fadlo R. Khuri, MD
EGFR and ALK Fadlo R. Khuri, MD President, American University of Beirut Professor of Medicine July 26, 2018 A great year end! Targeted Therapy for NSCLC: Evolving Landscape of Lung Adenocarcinoma NSCLC
More informationINNOVATION IN LUNG CANCER MANAGEMENT. Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy
INNOVATION IN LUNG CANCER MANAGEMENT Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy FIRST-LINE THERAPY FOR METASTATIC NSCLC IN 216 Stratification for EGFR, ALK
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationTargeted Therapies for Advanced NSCLC
Targeted Therapies for Advanced NSCLC Current Clinical Developments Friday, June 3, 2016 Supported by an independent educational grant from AstraZeneca Not an official event of the 2016 ASCO Annual Meeting
More informationTarget therapy nel NSCLC con EGFR M+ Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy)
Target therapy nel NSCLC con EGFR M+ Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy) cgridelli@libero.it First-Line Treatment of Advanced NSCLC EGFR-mutation analysis
More informationUnderstanding Options: When Should TKIs be Considered?
Advanced Stage Squamous NSCLC: Evolution and Increasing Complexity of the Therapeutic Landscape Understanding Options: When Should TKIs be Considered? David R. Gandara, MD University of California Davis
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationSequential treatment with afatinib and osimertinib in real-world patients with EGFR mutation-positive advanced NSCLC: the GioTag study
Scan the QR code for an electronic copy of the poster and supplementary material Sequential treatment with afatinib and osimertinib in real-world patients with EGFR mutation-positive advanced NSCLC: the
More informationPROGRESSION AFTER THIRD GENERATION TKI
PROGRESSION AFTER THIRD GENERATION TKI What next? National Cancer Center Hospital Yuichiro Ohe, MD Name of lead presenter Yuichiro Ohe employee of company and/or profit-making organization adviser of company
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationAfatinib in patients with EGFR mutation-positive NSCLC harboring uncommon mutations: overview of clinical data
Afatinib in patients with EGFR mutation-positive NSCLC harboring uncommon mutations: overview of clinical data Oscar Arrieta, 1 Pedro De Marchi, 2 Nobuyuki Yamamoto, 3 Chong-Jen Yu, 4 Sai-Hong I Ou, 5
More informationAFATINIB FOLLOWED BY OSIMERTINIB IN REAL-WORLD PATIENTS WITH EGFR MUTATION-POSITIVE NSCLC: AN OBSERVATIONAL STUDY
AFATINIB FOLLOWED BY OSIMERTINIB IN REAL-WORLD PATIENTS WITH EGFR MUTATION-POSITIVE NSCLC: AN OBSERVATIONAL STUDY Maximilian J. Hochmair, 1 Alessandro Morabito, 2 Desiree Hao, 3 Cheng-Ta Yang, 4 Ross A.
More informationTargeted therapy in NSCLC: do we progress? Prof. Dr. V. Surmont. Masterclass 27 september 2018
Targeted therapy in NSCLC: do we progress? Prof. Dr. V. Surmont Masterclass 27 september 2018 Outline Introduction EGFR TKI ALK TKI TKI for uncommon driver mutations Take home messages The promise of
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationInhibidores de EGFR Noemi Reguart, MD, PhD Hospital Clínic Barcelona IDIPAPS
Inhibidores de EGFR Noemi Reguart, MD, PhD Hospital Clínic Barcelona IDIPAPS Driver Mutations to Classify Lung Cancer Unknown 36% KRAS 25% EGFR 15% ALK 4% HER2 2% Double Mut 2% BRAF 2% PIK3CA
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationLudger Sellmann 1, Klaus Fenchel 2, Wolfram C. M. Dempke 3,4. Editorial
Editorial Improved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancer the Holy Grail in cancer treatment? Ludger Sellmann 1, Klaus Fenchel
More informationOverall survival with afatinib versus chemotherapy in patients with NSCLC harboring common EGFR
Overall survival with afatinib versus chemotherapy in patients with NSCLC harboring common EGFR mutations: subgroup analyses by race/ethnicity in LUX-Lung 3 and LUX-Lung 6 Yi-Long Wu, 1 Lecia V Sequist,
More informationIMPORTANT PATHWAYS TO TARGET IN (ADVANCED) NSCLC:
IMPORTANT PATHWAYS TO TARGET IN (ADVANCED) NSCLC: A focus on EGFR-inhibition and implications for clinical practice Floriana Morgillo, MD PhD and Morena Fasano, MD PhD Faculty of Medicine, Università degli
More informationVirtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More informationTargeting Acquired Resistance to EGFR Kinase Inhibitors: Beyond T790M Mutation
Targeting Acquired Resistance to EGFR Kinase Inhibitors: Beyond T790M Mutation James Chih-Hsin Yang, MD, PhD National Taiwan University Hospital National Taiwan University Cancer Center Taipei, Taiwan
More informationMaintenance Therapy for Advanced NSCLC: Which Patients, Which Approach?
Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Mark A. Socinski, MD Visiting Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology
More informationThe Rapidly Changing World of EGFR Mutation-Positive Acquired Resistance
The Rapidly Changing World of EGFR Mutation-Positive Acquired Resistance H. Jack West, MD Swedish Cancer Institute Seattle, WA GRACE Targeted Therapies Forum September 16, 2017 Cleveland, OH EGFR Mutation-Positive
More informationAgenda. 6:30pm 7:00pm. Dinner. 7:00pm 7:15pm. NSCLC Treatment in 2014: Focus on Use of 2nd Generation TKIs in Clinical Practice.
Agenda 6:30pm 7:00pm Dinner 7:00pm 7:15pm Welcome and Introductions Natasha Leighl, MD 7:15pm 7:50pm 7:50pm 8:00pm NSCLC Treatment in 2014: Focus on Use of 2nd Generation TKIs in Clinical Practice Questions
More informationPersonalized Treatment Approaches for Lung Cancer
Personalized Treatment Approaches for Lung Cancer California Thoracic Society 2018 Annual Carmel Conference January 27, 2018 Matthew Gubens, MD, MS Associate Professor of Medicine Chair, Thoracic Oncology
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationSlide 1. Slide 2. Slide 3. Disclosures. Personalized Medicine for Advanced NSCLC in East Asia. No conflicts related to this presentation
Slide 1 12 th International Lung Cancer Conference Personalized Medicine for Advanced NSCLC in East Asia Masahiro Tsuboi, M.D., Ph.D. Group Chair, Lung Cancer Surgical Study Group in Japan Clinical Oncology
More informationCURRENT STANDARD OF CARE OF LUNG CANCER. Maroun El-Khoury, MD Consultant Oncologist/Hematologist American Hospital Dubai President of Medical staff
CURRENT STANDARD OF CARE OF LUNG CANCER Maroun El-Khoury, MD Consultant Oncologist/Hematologist American Hospital Dubai President of Medical staff Biopsy: Establish Diagnosis, Determine Histologic Subtype,
More informationConsiderations for Choosing TKIs for Squamous NSCLC in the Era of Immunotherapy: Which Patients Could Benefit?
Considerations for Choosing TKIs for Squamous NSCLC in the Era of Immunotherapy: Which Patients Could Benefit? Barbara Melosky University of British Columbia, British Columbia Cancer Agency Faculty Disclosure
More informationPROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationPost-marketing observational study of Japanese patients with EGFR mutation-positive (EGFRm+) NSCLC treated with daily afatinib (final report)
Post-marketing observational study of Japanese patients with EGFR mutation-positive (EGFRm+) NSCLC treated with daily afatinib (final report) Nobuyuki Yamamoto, 1 Toshihiro Nukiwa, 2 Yoichi Nakanishi,
More informationTKI en primera línea EGFR mutado:importancia del equilibrio eficacia tolerabilidad
TKI en primera línea EGFR mutado:importancia del equilibrio eficacia tolerabilidad Dra Pilar Lianes Barragan Consorcio Sanitario del Maresme (Barcelona) Indice Epidemiología TKI en primera línea Eficacia
More informationNext Generation EGFR Inhibitors
Next Generation EGFR Inhibitors Tony Mok MD Li Shu Fan Medical Foundation Professor of Clinical Oncology Dept. of Clinical Oncology The Chinese University of Hong Kong EGFR TKIs First Generation -Gefitinib
More informationSuccesses and Challenges in Treating Squamous Cell Carcinoma of the Lung
Successes and Challenges in Treating Squamous Cell Carcinoma of the Lung Noemi Reguart,MD, PhD Hospital Clinic de Barcelona Barcelona, Spain SC-CRP-02660 Conversations in Oncology 2018 is a standalone
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationThe road less travelled: what options are available for patients with advanced squamous cell carcinoma?
Robert Pirker Medical University of Vienna Vienna, Austria The road less travelled: what options are available for patients with advanced squamous cell carcinoma? Disclosures Honoraria for advisory board/consulting
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More informationSecond-line treatment for advanced NSCLC
UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Life was so simple back in 2008 Di
More informationEGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS
EGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS Federico Cappuzzo Istituto Clinico Humanitas IRCCS Rozzano-Italy The EGFR/HER Family Ligand binding domain
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationOsimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study
Osimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study Abstract 9002 Yang JC, Kim DW, Kim SW, Cho BC, Lee JS, Ye X, Yin X, Yang
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationTargeted/Immunotherapy & Molecular Profiling State-of-the-art in Cancer Care
Targeted/Immunotherapy & Molecular Profiling State-of-the-art in Cancer Care Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland
More informationEGFR Mutation-Positive Acquired Resistance: Dominance of T790M
Treatment of EGFR Mutation-Positive Acquired Resistance: T790M+ or T790M- H. Jack West, MD Swedish Cancer Institute, Seattle, WA EGFR Mutation-Positive Acquired Resistance: Dominance of T790M Yu, Clin
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More information1st line chemotherapy and contribution of targeted agents
ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER 1st line chemotherapy and contribution of targeted agents Yi-Long Wu Guangdong Lung Cancer Institute Guangdong General Hospital Guangdong Academy
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationTargeted therapies for advanced non-small cell lung cancer. Tom Stinchcombe Duke Cancer Insitute
Targeted therapies for advanced non-small cell lung cancer Tom Stinchcombe Duke Cancer Insitute Topics ALK rearranged NSCLC ROS1 rearranged NSCLC EGFR mutation: exon 19/exon 21 L858R and uncommon mutations
More informationAURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC?
Editorial Page 1 of 5 AURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC? Terry L. Ng, D. Ross Camidge Division of Medical Oncology, Department of Medicine, University of Colorado
More informationLung Cancer Update 2016 BAONS Oncology Care Update
Lung Cancer Update 2016 BAONS Oncology Care Update Matthew Gubens, MD, MS Assistant Professor Chair, Thoracic Oncology Site Committee UCSF Helen Diller Family Comprehensive Cancer Center Disclosures Consulting
More informationSecond-line treatment for advanced NSCLC
Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY DISCLOSURE OF INTEREST Speaker Bureau: Eli Lilly, MSD, BI, BMS, Roche, AZ UNIVERSITY
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer Page 1 of 52 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Molecular Analysis for Targeted
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationNext-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib
BioDrugs (2015) 29:167 183 DOI 10.1007/s40259-015-0130-9 REVIEW ARTICLE Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib Vera Hirsh 1 Published online: 30 June 2015 The
More informationTargeted Cancer Therapies
Targeted Cancer Therapies Primary Care Training Programme 14 th February 2018 Sin Chong Lau Consultant in Medical Oncology Financial Disclosure Honoraria: Amgen, Pfizer, Roche, Sanofi, Servier Meetings:
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationMonoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs
Monoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs Corey J Langer, MD, FACP Director Thoracic Oncology Abramson Cancer Center Professor
More informationAntiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout
More informationPage: 1 of 27. Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer
Last Review Status/Date: December 2014 Page: 1 of 27 Non-Small-Cell Lung Cancer Description Over half of patients with non-small-cell lung cancer (NSCLC) present with advanced and therefore incurable disease,
More informationEpidermal growth factor receptor (EGFR) mutations are
Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3 Terufumi Kato, 1 Hiroshige Yoshioka,
More informationSequence or intercalation of use of targeted agents and Chemotherapy Definition of progression under TKI
ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER Strategic Approaches Sequence or intercalation of use of targeted agents and Chemotherapy Definition of progression under TKI Yi-Long Wu Guangdong
More informationPATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER
PATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER Martin Reck Department of Thoracic Oncology LungClinic Grosshansdorf Germany DISCLOSURES Honoraria for
More informationRecent Advances in Lung Cancer: Updates from ASCO Updates from ESMO, AACR and ASCO
Recent Advances in Lung Cancer: Updates from ASCO 2018 Updates from ESMO, AACR and ASCO Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationNSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza
NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine
More informationK-Ras signalling in NSCLC
Targeting the Ras-Raf-Mek-Erk pathway Egbert F. Smit MD PhD Dept. Pulmonary Diseases Vrije Universiteit VU Medical Centre Amsterdam, The Netherlands K-Ras signalling in NSCLC Sun et al. Nature Rev. Cancer
More informationManagement of EGFR-mutant NSCLC. Jonathan Riess, MD, MS Assistant Professor UC Davis Comprehensive Cancer Center
Management of EGFR-mutant NSCLC Jonathan Riess, MD, MS Assistant Professor UC Davis Comprehensive Cancer Center Disclosures Research Funding: Merck, Novartis, AstraZeneca, Millenium Consulting: AbbVie,
More informationDo You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement. Reference Slides Introduction
Do You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement Reference Slides Introduction EML4-ALK Fusion Oncogene Key Driver in 3% to 7% NSCLC Inversion or Translocation
More informationFirst line erlotinib for NSCLC patients not selected by EGFR mutation: keep carrying the TORCH or time to let the flame die?
Perspective First line erlotinib for NSCLC patients not selected by EGFR mutation: keep carrying the TORCH or time to let the flame die? Jared Weiss Multidisciplinary Thoracic Oncology Program, Lineberger
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More informationMonthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016 Jae Kim, MD City of Hope Comprehensive Cancer Center Karen Reckamp,
More informationPersonalized Medicine for Advanced NSCLC in East Asia
Personalized Medicine for Advanced NSCLC in East Asia - Update treatment strategy for NSCLC based on Japanese clinical practice guideline - Masahiro Tsuboi, M.D., Ph.D. Associate-professor, School of Medicine,
More informationEGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence
102 Journal of Cancer Research Updates, 2012, 1, 102-107 EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence Kenichi
More informationExploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Suresh S. Ramalingam, MD Director of Thoracic Oncology Associate Professor Emory University Atlanta,
More informationEGFR-M+ NSCLC: Mechanistic and Clinical Considerations for Choosing the Best TKI
EGFR-M+ NSCLC: Mechanistic and Clinical Considerations for Choosing the Best TKI 217 Conversations in Oncology in Shanghai, China Dr. Daniel SW Tan Division of Medical Oncology, National Cancer Centre
More informationPersonalized maintenance therapy in advanced non-small cell lung cancer
China Lung Cancer Research Highlight Personalized maintenance therapy in advanced non-small cell lung cancer Kazuhiro Asami, Kyoichi Okishio, Tomoya Kawaguchi, Shinji Atagi Department of Clinical Oncology,
More informationNational Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan;
Competing central nervous system or systemic progression analysis for patients with EGFR mutation-positive NSCLC receiving afatinib in LUX-Lung 3, 6, and 7 James C.-H. Yang, 1 Yi-Long Wu, 2 Vera Hirsh,
More informationSpecial Thanks! 10/5/2018. Page 1
Disclaimer This slide deck in its original and unaltered format is for educational purposes. All materials contained herein reflect the views of the faculty, and not those of Creative Educational Concepts,
More informationOriginal Article. Abstract
Japanese Journal of Clinical Oncology, 2015, 45(7) 670 676 doi: 10.1093/jjco/hyv054 Advance Access Publication Date: 15 April 2015 Original Article Original Article Efficacy of chemotherapy after first-line
More informationOTRAS TERAPIAS BIOLÓGICAS EN CPNM: Selección y Secuencia Óptima del Tratamiento
OTRAS TERAPIAS BIOLÓGICAS EN CPNM: Selección y Secuencia Óptima del Tratamiento Dolores Isla Servicio de Oncología Médica HCU Lozano Besa de Zaragoza 2008 Selection Factors in Advanced NSCLC ( 8y ago)
More informationAFATINIB* 1. WHAT IS AFATINIB? 2. HOW DOES AFATINIB WORK? B A C K G R O U N D E R
AFATINIB* B A C K G R O U N D E R 1. What is afatinib? 2. How does afatinib work? 3. Data overview: the LUX-Lung clinical trial programme 4. Data overview: the LUX-Head and Neck clinical trial programme
More informationPresented at the European Society of Medical Oncology (ESMO), Munich, Germany, October 2018
Effectiveness of afatinib in clinical practice first results of the GIDEON trial: a prospective non-interventional study in EGFR-mutated NSCLC in Germany Wolfgang M. Brueckl 1 *, Eckart Laack 2, Martin
More information